Lower-cost denosumab options are now available in Denmark.
Following Prolia’s (denosumab) patent expiry in November 2025, Medicinrådet states that clinicians should prescribe the cheapest biosimilar alternative when initiating or switching denosumab treatment for osteoporosis.
What changed
- Several denosumab biosimilar injection solutions (60 mg/ml) have received general, clause-based reimbursement from the Danish Medicines Agency.
- Current prices are published on Medicinpriser.dk.
Why the prescription matters
- For biosimilars, pharmacies cannot offer patients the cheapest product through substitution.
- Medicinrådet therefore asks prescribers to choose the lowest-priced option so patients can benefit from the lower prices.
Biosimilars listed
- Izamby, Jubbonti, Junod, Obodence, Osvyrti, ZADENVI, Ponlimsi and Stoboclo.
Reimbursement clause: patients with osteoporosis where oral bisphosphonates are insufficient, contraindicated, or not tolerated.
